What is Endra Life Sciences Inc's earnings per share (EPS)?

Endra Life Sciences Inc (NDRA) reported diluted earnings per share of $-8.93 for fiscal year 2025. This represents a 84.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Endra Life Sciences Inc Financials

NDRA

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Endra Life Sciences Inc (NDRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.74x

For every $1 of reported earnings, Endra Life Sciences Inc generates $0.74 in operating cash flow (-$5.2M OCF vs -$7.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$5.7M

YoY+46.9%

Endra Life Sciences Inc's EBITDA was -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.9% from the prior year.

Net Income

-$7.0M

YoY+38.9%

Endra Life Sciences Inc reported -$7.0M in net income in fiscal year 2025. This represents an increase of 38.9% from the prior year.

EPS (Diluted)

$-8.93

YoY+84.3%

Endra Life Sciences Inc earned $-8.93 per diluted share (EPS) in fiscal year 2025. This represents an increase of 84.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$5.2M

YoY+29.9%

Endra Life Sciences Inc generated -$5.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 29.9% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

YoY+131.1%

Endra Life Sciences Inc had 1M shares outstanding in fiscal year 2025. This represents an increase of 131.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$1.8M

YoY-42.0%

5Y CAGR-20.7%

Endra Life Sciences Inc invested $1.8M in research and development in fiscal year 2025. This represents a decrease of 42.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$17K

YoY+8.0%

5Y CAGR-25.5%

Endra Life Sciences Inc invested $17K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 8.0% from the prior year.

NDRA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	$0
R&D Expenses	$1.8M-42.0%	$3.2M-36.2%	$5.0M-23.7%	$6.6M+19.5%	$5.5M-7.4%	$5.9M
SG&A Expenses	$3.7M-47.2%	$7.1M+50.2%	$4.7M-9.2%	$5.2M+4.7%	$4.9M-1.2%	$5.0M
Operating Income	-$5.8M+46.7%	-$10.8M-2.8%	-$10.5M+20.0%	-$13.2M-14.4%	-$11.5M0.0%	-$11.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$7.0M+38.9%	-$11.5M-14.4%	-$10.1M+23.7%	-$13.2M-17.3%	-$11.2M+4.2%	-$11.7M
EPS (Diluted)	$-8.93+84.3%	$-56.94	$-2766.85	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$432K+13.4%	$381K-27.9%	$529K	N/A	$794K+10.9%	$716K-31.2%	$1.0M	N/A
SG&A Expenses	$893K+4.9%	$851K-2.3%	$872K	N/A	$631K-53.3%	$1.4M-9.9%	$1.5M	N/A
Operating Income	-$1.4M-5.4%	-$1.3M+11.4%	-$1.5M	N/A	-$1.5M+32.4%	-$2.2M+19.8%	-$2.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	N/A	$0	$0	$0	N/A
Net Income	-$1.6M-30.2%	-$1.2M-18.3%	-$1.0M	N/A	-$2.4M-5.6%	-$2.2M+19.7%	-$2.8M	N/A
EPS (Diluted)	$-2.10	N/A	N/A	N/A	$-9.54	N/A	N/A	N/A

NDRA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$4.5M-34.1%	$6.8M-27.2%	$9.3M-28.0%	$12.9M+46.9%	$8.8M
Current Assets	N/A	$3.4M+13.2%	$3.0M-43.6%	$5.4M-55.5%	$12.1M+47.4%	$8.2M
Cash & Equivalents	N/A	$3.2M+14.0%	$2.8M-42.0%	$4.9M-48.3%	$9.5M+30.9%	$7.2M
Inventory	N/A	$0-100.0%	$2.6M-0.8%	$2.6M+105.9%	$1.3M+117.9%	$590K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$1.9M+72.8%	$1.1M-47.1%	$2.1M-1.0%	$2.1M+31.0%	$1.6M
Current Liabilities	N/A	$605K-33.0%	$903K-47.0%	$1.7M+10.4%	$1.5M+56.5%	$987K
Long-Term Debt	N/A	$0	$0	$0-100.0%	$547K	N/A
Total Equity	N/A	$2.6M-54.8%	$5.7M-21.5%	$7.2M-33.2%	$10.8M+50.4%	$7.2M
Retained Earnings	N/A	-$103.4M-12.5%	-$91.9M-12.3%	-$81.9M-19.2%	-$68.7M-19.8%	-$57.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$2.0M-30.0%	$2.8M-11.4%	$3.2M-28.8%	$4.5M-46.9%	$8.4M-19.8%	$10.4M+106.3%	$5.1M-25.1%	$6.8M
Current Assets	$1.0M-43.4%	$1.9M-15.0%	$2.2M-36.5%	$3.4M-30.8%	$5.0M-26.1%	$6.7M+428.4%	$1.3M-58.1%	$3.0M
Cash & Equivalents	$794K-56.1%	$1.8M-12.4%	$2.1M-36.1%	$3.2M-31.9%	$4.7M-25.9%	$6.4M+464.1%	$1.1M-60.0%	$2.8M
Inventory	$0	$0	$0	$0-100.0%	$2.7M0.0%	$2.7M0.0%	$2.7M+3.4%	$2.6M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M+34.3%	$1.3M-5.9%	$1.4M-25.1%	$1.9M+6.6%	$1.8M+22.5%	$1.4M+6.3%	$1.4M+24.4%	$1.1M
Current Liabilities	$800K+38.8%	$577K+1.9%	$566K-6.5%	$605K-25.7%	$814K-39.7%	$1.4M+11.0%	$1.2M+34.7%	$903K
Long-Term Debt	N/A	N/A	N/A	$0	N/A	N/A	$0	$0
Total Equity	$171K-88.4%	$1.5M-16.0%	$1.8M-31.5%	$2.6M-61.2%	$6.6M-26.6%	$9.0M+143.2%	$3.7M-34.6%	$5.7M
Retained Earnings	-$107.3M-1.5%	-$105.7M-1.2%	-$104.5M-1.0%	-$103.4M-4.2%	-$99.3M-2.4%	-$96.9M-2.4%	-$94.7M-3.0%	-$91.9M

NDRA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.2M+30.0%	-$7.4M+22.5%	-$9.5M+25.2%	-$12.8M-14.8%	-$11.1M-3.5%	-$10.7M
Capital Expenditures	$17K+8.0%	$16K-52.8%	$34K-83.3%	$203K+350.2%	$45K-40.3%	$75K
Free Cash Flow	-$5.2M+29.9%	-$7.4M+22.6%	-$9.6M+26.1%	-$13.0M-16.2%	-$11.2M-3.2%	-$10.8M
Investing Cash Flow	-$3.0M-23479.9%	-$13K+48.2%	-$25K+87.8%	-$203K-350.2%	-$45K+40.3%	-$75K
Financing Cash Flow	$5.7M-26.6%	$7.8M+3.9%	$7.5M-10.5%	$8.4M-37.3%	$13.4M+12.9%	$11.9M
Dividends Paid	N/A	N/A	N/A	$0-100.0%	$121K-69.4%	$396K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.2M-4.5%	-$1.1M+13.9%	-$1.3M+14.7%	-$1.5M+8.5%	-$1.7M+20.5%	-$2.1M+2.8%	-$2.1M+1.4%	-$2.2M
Capital Expenditures	$0	$0-100.0%	$17K	$0	$0+100.0%	-$11K-140.7%	$27K+292.2%	$7K
Free Cash Flow	-$1.2M-4.5%	-$1.1M+15.0%	-$1.3M+13.5%	-$1.5M+8.5%	-$1.7M+20.9%	-$2.1M+3.5%	-$2.2M+0.5%	-$2.2M
Investing Cash Flow	$0	$0+100.0%	-$17K	$0	$0-100.0%	$11K+146.2%	-$24K-1144.1%	$2K
Financing Cash Flow	$149K-82.6%	$857K+488.1%	$146K	$0-100.0%	$2K-100.0%	$7.3M+1465.0%	$469K-72.0%	$1.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NDRA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-449.5%-271.7pp	-177.8%+5.2pp	-182.9%-78.8pp	-104.2%+59.4pp	-163.5%
Return on Assets	N/A	-258.5%-109.5pp	-149.0%-6.8pp	-142.1%-54.9pp	-87.2%+46.5pp	-133.8%
Current Ratio	N/A	5.67+2.3	3.36+0.2	3.16-4.7	7.83-0.5	8.32
Debt-to-Equity	N/A	0.000.0	0.000.0	0.00-0.1	0.05-0.2	0.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-931.2%-848.0pp	-83.2%-24.1pp	-59.1%	N/A	-35.6%-10.8pp	-24.8%+50.3pp	-75.1%	N/A
Return on Assets	-81.3%-37.6pp	-43.7%-11.0pp	-32.7%	N/A	-28.1%-6.7pp	-21.3%+33.5pp	-54.9%	N/A
Current Ratio	1.31-1.9	3.21-0.6	3.85-1.8	5.67-0.4	6.10+1.1	4.97+3.9	1.04-2.3	3.36
Debt-to-Equity	10.46+9.6	0.91+0.1	0.81+0.8	0.00-0.3	0.27+0.1	0.16+0.2	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Check Cap CHEK

$9.4M

Applied Dna Scie APDN

$7.3M

bioAffinity Tech BIAF

$17.6M

Mainz Biomed NV MYNZ

$10.6M

XWELL Inc XWEL

$6.2M

Frequently Asked Questions

Is Endra Life Sciences Inc profitable?

No, Endra Life Sciences Inc (NDRA) reported a net income of -$7.0M in fiscal year 2025.

What is Endra Life Sciences Inc's EBITDA?

Endra Life Sciences Inc (NDRA) had EBITDA of -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Endra Life Sciences Inc's free cash flow?

Endra Life Sciences Inc (NDRA) generated -$5.2M in free cash flow during fiscal year 2025. This represents a 29.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Endra Life Sciences Inc's operating cash flow?

Endra Life Sciences Inc (NDRA) generated -$5.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Endra Life Sciences Inc's capital expenditures?

Endra Life Sciences Inc (NDRA) invested $17K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Endra Life Sciences Inc spend on research and development?

Endra Life Sciences Inc (NDRA) invested $1.8M in research and development during fiscal year 2025.

How many shares does Endra Life Sciences Inc have outstanding?

Endra Life Sciences Inc (NDRA) had 1M shares outstanding as of fiscal year 2025.

Are Endra Life Sciences Inc's earnings high quality?

Endra Life Sciences Inc (NDRA) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.